Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL11: Obinutuzumab vs Rituximab + Chlorambucil in CLL
NCT01998880Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2009
- Primary completion
- Aug 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by Roche. Started Dec 2009; status: completed.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01998880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01998880.